Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients with rare diseases and cancers are being signed up to a massive genetic study that could improve the treatment of their conditions.

100,000 Genomes ProjectFrom today clinicians will be asking eligible patients from around the country for genetic samples as part of the national 100,000 Genomes Project. The project is run by Oxford University Hospitals Trust (OUH), with the laboratory a collaboration of the Oxford Molecular Diagnostics Centre (OMDC) at the John Radcliffe Hospital and Oxford University.

SRT nurses and Biorepository Technicians from the Nuffield Department of Surgical Sciences will play a key role by recruiting the patients and collecting the blood and tissue samples that will be used in the project.

The team will collect around 1,200 samples from about 600 cancer patients and around 2,000 samples from about 660 rare disease patients. Samples will also be taken for other types of analyses for further research and extensive clinical outcome data will be collected. All samples will be sequenced by Illumina, the 100,000 Genomes Project’s sequencing partner.

Read the full story on the OUH website.


Gene study offers new hope to cancer patients

One patient to benefit from a pilot study into genetic sequencing is Oxford University’s Professor Kevin Gatter, who was diagnosed with rare metastatic prostate cancer in December. Read the full story in the Oxford Mail.